Wedbush Reiterates Outperform Rating on Sutro Biopharma, Keeps $60 Target
Wedbush reiterated its Outperform rating and $60 price target on Sutro Biopharma. The target implies 470.3% upside from the Oct. 14 close of $10.52.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.